IQVIA is a world leader in using data, technology, advanced analytics and expertise to help customers drive healthcare forward. Together with the companies we serve, we are enabling a more modern and effective healthcare system and creating breakthrough solutions that transform business and patient outcomes.
S3 Connected Health are the specialist digital health partner for life sciences companies.
We create regulated digital health solutions, from digital companions, chronic disease, and treatment management to digital therapeutics, that improve the lives of people with acute and chronic conditions.
We have delivered award-winning, regulatory-compliant solutions across 20 therapy areas and in more than 50 countries. Our scalable and secure solutions improve disease management, differentiate pharma products, and deliver new therapeutic interventions.
Affinial, our digital health platform offers our partners the opportunity to develop custom digital health solutions that address specific patient and disease challenges, while leveraging pre-built services that provide best practice implementation with a reduced cost and time to market.
S3 Connected Health supports our partners in pharma at all stages of their journey, from discovery through to solution creation and operation of regulated digital health solutions that fit corporate and brand commercial strategies.
BrightInsight provides the leading global regulated digital health platform for biopharma and medtech. Every line of code of our BrightInsight Platform is built under a Quality Management System to support and optimize regulated drugs, devices and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement. The BrightInsight™ Platform uses software and services to capture, transmit and analyze data from CE-marked and FDA-regulated medical devices, combination products, apps and Software as a Medical Device, in compliance with global security, privacy and regulatory requirements. Deployed as a managed service, the platform accelerates time to market for biopharma and medtech companies, reduces the cost of implementation and maintenance versus a custom solution, and scales across products and global markets.
At our core is perseverance, a fierce determination to overcome any obstacle regardless of setbacks, on behalf of patients and their loved ones. We place greater value on what we can achieve together than on what we can do alone because the needs of those we serve always come first. We will not be bound by doing what’s been done before. Instead, we free ourselves from preconceived notions to discover solutions that advance patient care. Our mission is clear: Otsuka-people, creating new products for better health worldwide.
Customer-centric, Omnichannel Campaigns for Healthcare Audiences
Our vision is to change healthcare professionals’ perception of content produced by the pharmaceutical, biotechnology and medical devices industries. We want to create a world where the information produced by our clients is respected and admired, so that engagement with it becomes meaningful. Ultimately, we want to help you provide your customers with content and information that will lead to better clinical decision-making and outcomes for patients.
CREATION Knowledge is a website and eJournal for healthcare marketers,
communicators and leaders. Launched in 2008, the publication is trusted for its
expert content focused on how and why healthcare professionals use social media,
revealing the insights available from listening to their online conversations.
It is a part of CREATION.co, which provides insights and consulting to inform health
strategy, communications and policymaking among some of the world’s largest
healthcare companies, government organisations and NGOs.
All this is made possible through CREATION Pinpoint®, the world’s only AI-powered
global database of nearly 3M healthcare professionals’ social media profiles,
analysing the collective intelligence of over 1.7Bn social media posts by
professionals on the front lines of healthcare.
DTx Europe is coming back to London ! Bringing you 2 days of cutting-edge content and an industry leading speaker faculty, this event provides you with a one-stop shop of all things digital therapeutics ensuring you leave the event with key takeaways and the knowledge to accelerate your own digital journey. Join us on Day 1 for the first ever tracked DTx Europe, splitting into The Evidence and The Commercial paths. Whatever you’re looking for we got you covered!
Experts from every stakeholder within the digital therapeutics space will be coming down to London in June 2023. Calling to every corner of the industry, join your peers from leading DTx companies, Pharma, Payers, Providers, Government Bodies, Academia, Policy Makers and more. Step away from the screen for 2 days of industry-defining discussions and catch up with old and make new connections within the field.
The time has come to meet in-person once again! Join your peers for live presentations and engaging discussions. DTx Europe will be diving into key areas such as Commercialisation, Regulation, Clinical Trials, Patient Insights, Provider Adoption, User Engagement,
Partnerships and more. No matter where your interest lies, we’ve got you covered.
“It is by far the people that make these DTx events. The DTx series brings some of the best in class, and I look forward to seeing the group four times a year.”
“The DTx Europe conferences remain the most important event for the digital therapeutics space in Europe. This is my primary go-to event, when I want to know the latest and greatest, and meet my peers to exchange ideas and insights.”
“You’re really following the conversations that are happening and so a lot of times when I look at the agenda I think ‘these are exactly all the things that I want to talk or hear about’”
“DTx Europe is one of the most exciting events of the year in healthcare – where we hear from leaders who are pushing the boundaries to deliver world-class care for patients globally. Really looking forward to the next event!”
“I just see digital health, connected devices, digital therapeutics as the next generation of how we improve patient outcomes. And it’s the reason why we come to DTx because it’s the one event where everyone here has that same mission.“
“This is a must-attend event for everyone involved in digital therapeutics and digital care companions. In a phase of steady growth for the DTx market, I can’t wait to join my peers and get their perspectives at the next DTx Europe”
2023 Speaker Faculty
Edouard is the Co-Founder and CEO of Tilak Healthcare, a unique video game studio creating clinically validated medical mobile games to help monitor and rehabilitate patients affected by chronic diseases.
For more than 10 years, Edouard worked in the video game industry at Gameloft, a company developing and editing mobile video games, where he successively held the positions of Project manager in Paris, then Lead Producer in New Orleans and finally managing Director of Gameloft Madrid.
Driven by his passion for innovation and technology, he was also a writer for TechCrunch France, covering mobile apps, 2.0 web and entertainment topics.
Dr Mark Jenkins is co-founder and Medical & UK Managing Director at Oviva, a NHS service provider using app-based care to transform access and outcomes in weight management for people living with type 2 diabetes and obesity.
Mark qualified from Guy’s, King’s & St Thomas School of Medicine and trained in academic nephrology (the study of kidneys) at Guy’s & St Thomas NHS Foundation Trust before working as a management consultant at the Boston Consulting Group on several NHS system transformation projects.
Today, Mark leads Oviva’s efforts supporting the NHS, overseeing our UK team of over 300 people, most of whom are clinicians including dietitians, nurses, doctors and health coaches.
Oviva is Europe’s leading provider of digitally-enabled behaviour change services, having treated over 300,000 patients to date and operating in 36 NHS ICSs, as well as in Germany, Switzerland, and France.
After a medical apprenticeship and studies in medical technology, I worked as a scientific
employee at the Federal Institute for Drugs and Medical Devices for more than seven years.
Among others, in the areas of approval of clinical trials with medical devices and vigilance.
The last two years were spent in the field of digital health applications (DiGA) as deputy
head of the according unit. In this area, I was intensively involved in the development of the
German DiGA fast-track and helped to design it. Since January 22, I have been in charge of
market access at Sympatient and now dedicate myself to solving the worldwide anxiety
Kate is a Senior Principal based in London and is part of the Integrated Digital Health
COE. She has over 13 years of consulting experience in the US and Europe, working
with a broad range of pharmaceutical, biotechnology, diagnostic, and digital health
clients. Kate has expertise in market access strategy, launch pricing, companion
diagnostics, and commercial strategy in digital health. Kate holds a B.A. from
Princeton University in Molecular Biology
Dr Rayna Patel is a medical doctor & neuroscientist with an MPhil in Translational Medicine. She has extensive experience in academia (Cambridge, Harvard, MIT, Columbia) and was an Associate Fellow of Clare Hall College, Cambridge. Rayna has subsequently held strategic & commercial roles in government policy, tech startups & the Cabinet Office’s Nudge Unit, where she used behavioural science to rewire patient behaviours through digital products.
She is currently CEO and Co-Founder of Vinehealth, a digital platform using a combination of behavioural science and AI to improve the quality of life and survival of cancer patients, whilst generating crucial real-world data to better inform healthcare delivery and drug development.
As co-founder and managing director Christian is in charge of sales, market access, and reimbursement for Sympatient – the first digital anxiety clinic. He has a strong passion for solving complex problems in healthcare systems to ultimately enable better access to care for patients. Christian holds a degree in economics from Jacobs University, an MPhil from the University of Cambridge, and has been a visiting student at Harvard University.
He has been involved in wide-scale system implementation projects to improve efficiency and patient outcomes and has a deep understanding of the challenges of the referral process, as well as the real-world barriers to successfully identifying and inviting eligible patients to Diabetes programmes.
He also has a medical management business where he works with leaders and teams to increase efficiency of care delivery. He uses a Systems Thinking approach and tries to incorporate the best IT solutions.
Oliver is an Associate Principal based in Germany and is part of the Integrated Digital
Health COE. He has spent over 10 years driving digital health initiatives across the
UK’s National Health System – leading teams focused on the deployment of AI digital
triage solutions, remote monitoring, virtual wards and population health analytics. He
has recently worked with global life science organisations, supporting their digital
health strategies and helping them to access Germany’s DTx prescription approach –
‘DiGA’. He holds a BSc. Genetics and an MSc. Health Informatics from University
Yury Rozenman is the SVP of Pharmaceutical and Life Sciences at Propeller. In this role, he leads the company’s strategy, vision and oversees execution of all global business development activities. Prior to joining Propeller, Yury was the head of healthcare and life sciences industry partnerships at AWS where he was responsible for the development of life sciences vertical solutions, marketing programs, joint GTM strategy and execution on the global basis. Yury has 30 years of experience within the industry in pharmaceutical research and development both as a team leader and group research manager. He has worked in diagnostics and medical devices, and has been involved in the development and launch of world-class drugs and diagnostic tests.
Arvind joined atai Life Sciences in 2021 as Vice President, Digital Strategy and Operations, and is responsible for establishing and implementing atai’s Digital Therapeutics and Precision Psychiatry strategy. Prior to joining atai, Arvind was the Chief Operating Officer of Oxford VR, where he was responsible for Operations, Strategy, and Business Development. Oxford VR received Breakthrough Device designation from the FDA for the treatment of serious mental illnesses and was acquired by US operator BehaVR in 2022.
Before joining Oxford VR, Arvind was an Investment Manager at Epiris Private Equity (“Epiris”), where he was responsible for the buy-out, management, and digital transformation of companies between £100m – £500m in valuation. At Epiris, Arvind deployed and exited over £400m and £200m of capital respectively and sat on 9 Executive Boards. Arvind started his professional career at NM Rothschild & Sons where he was Vice President, Healthcare Mergers & Acquisitions.
Arvind holds a Bachelor’s and Master’s degree in Molecular and Cellular Biochemistry from the University of Oxford with dissertations in Cell Cycle Replication (Professor Kearsey) and Vaccinology (Dame Professor Gilbert).
Ryan is Managing Partner at MassMutual Ventures (MMV), leading investments across Europe and Asia-Pacific. He has over 20 years of experience as an investor, operator and board member, working with companies from seed to IPO and beyond. Ryan started his career in public markets. He was formerly an Executive Director at Goldman Sachs, and a Principal at a multi-strategy hedge fund. As an operator, Ryan has worked on strategy, product, business development, international expansion and fundraising. Ryan holds a BSc in Computer Science and an MSc in Psychology, with post-graduate research experience in Cognitive Neuroscience.
For our 5th year anniversary DTx Europe will be coming to London at the British Medical Association House. Designed by Sir Edwin Lutyens – one of the greatest British architects of the twentieth century – and opened by King George V. The remarkable space will be a perfect for our DTx community.
Situated in the heart of London right next to King’s Cross St Pancras Station, we look forward to seeing you in the summer.
Please see some of the nearby accommodation options available:
- Ambassadors Bloomsbury, 4 Stars
- Hilton Euston, 4 Stars
- Pullman London St Pancras, 4 Stars
Partner With Us
The DTx summits are the premier events for senior executives from DTx companies, Pharma, Investors, HCPs and Payers.
DTx Europe: London 2023 is the 17th summit in the DTx series. We believe that getting the right mix of partners is critical for a successful summit for you and our attendees. The DTx summit provides a rare opportunity to showcase your business to a world-class audience.
You will be impressed with our service and truthfulness. We will be honest with you throughout the process from deciding which option is right for you to delivery on-site.
Spaces are limited this year, please contact our commercial managers, Joshua (email@example.com) and Christian (firstname.lastname@example.org) to discuss opportunities for involvement.
Register for the Event
For pricing and booking options please click the button to go to the registration page.